SeaStar Medical Holding Corp (NAS:ICU)

Q2 2025 SeaStar Medical Holding Corp Earnings Call Transcript

Aug 13, 2025 / 08:30 PM GMT

Release Date Price: $7.27 (-0.36%)

Transcript 10-Q

Key Points

Positve

SeaStar Medical Holding Corp (ICU) reported a 370% increase in revenue in the first six months of 2025 compared to the first six months of launch.
The company enrolled 125 patients in the neutralized AKI trial, showing significant progress in their clinical trials.
Positive survival results were announced from the first 20 pediatric patients treated with Quell immune, with a 75% survival rate.
SeaStar Medical Holding Corp (ICU) secured three new Qualimmune customers, including top-rated US-based children's hospitals.
The company raised additional capital to strengthen its balance sheet, including $12.4 million through public and direct offerings.

Negative

Sales of the Quimmune product are expected to be 'lumpy' in the first year, indicating potential revenue volatility.
The company is still in the process of enrolling patients for its neutralized AKI pivotal trial, with 75 patients yet to be enrolled.
Operating expenses remain high, with a reported $2.1 million in the second quarter of 2025.
The company reported a net loss of $2 million for the second quarter of 2025.
Despite progress, the company still faces the challenge of expanding customer adoption and understanding patient presentation cadence.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ICU.OQ - SeaStar Medical Holding Corp
Q2 2025 SeaStar Medical Holding Corp Earnings Call
Aug 13, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the CSA Medical 2nd quarter financial results conference call. All lines have been placed on mute to prevent any background noise. To the speaker's remarks, there will be a question and answer session. To ask a question, simply press star, followed by the number one on your telephone keypad. To withdraw your question, press one again. It is now my pleasure to turn the call over to Jackie Kosman. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.